case_images: PMC11230130_01
case_images: Disease progression, treatment and outcome of the patient. (A) Timeline of the disease progression and relevant treatments of the patient. (B) The CT gram of the patient during the treatment and follow-ups. (C) Serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels of the patient during the treatment and follow-ups.
case_images: ITT-13-343-g0002.jpg
case_images: PMC11230130_01_ITT-13-343-g0002.jpg
case_images: f0002
case_images: Specifically, each cycle included a two-week medication phase, during which the patient ingested 1.5 g of capecitabine in the morning and 1.0 g in the afternoon, followed by a one-week cessation period (Figure 2A).  Three weeks post-injection, on 8 August 2022, CT examination showed a significant tumour shrinkage with the tumour diameter from 12 cm to 4.5 cm (Figure 2B). In addition, serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (Ca19-9) levels were dropped from 90.7 ng/mL and 66.77 U/mL to 11.25 ng/mL and 13.49 U/mL, respectively, after 3 weeks of the H101 injection, and remained within the normal range (<5.1 ng/mL for CEA and <27 U/mL for Ca19-9) during the subsequent treatment and follow-up period (Figure 2C).